ArticleNPJ breast cancer2025
Triple-negative breast cancer modifies the systemic immune landscape and alters neutrophil functionality.
Article in NPJ breast cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Liquid biopsy reveals the immune status and protein profiles linked to CTC burden and clinical outcomes in metastatic breast cancer.Journal of experimental & clinical cancer research : CR · 2026Trial
- The peripheral immune landscape of human breast cancer.Oncoimmunology · 2026Review
- Breast Cancer-Derived AZU1 Educates Neutrophils to Promote Tumor Progression and Metastasis Through PAD4-Dependent Extracellular Trap Formation.Molecular carcinogenesis · 2026Article
- γδ T cells and cancer.The Journal of clinical investigation · 2026Review
- Smart nanocarriers in triple-negative breast cancer: recent advances in targeting and translational application.Drug delivery and translational research · 2026Review
- Systemic Inflammatory and Hematological Profiles in Triple-Negative Breast Cancer: A Study from a Senegalese Cohort.Diagnostics (Basel, Switzerland) · 2026Article
- Multi-omics profiling uncovers immune-molecular clusters with distinct chemo-immunotherapeutic vulnerabilities in a mouse model of triple-negative breast cancer.Molecular cancer · 2026Article
- Modulating N1 and N2 neutrophils in breast cancer: potential therapeutic approaches - a narrative review.Annals of medicine and surgery (2012) · 2026Review
- Ultrasonographic features and inflammatory status associated with tumor size in breast invasive ductal carcinoma.American journal of translational research · 2026Article
- Systemic Immune Profiling Reveals Candidate Biomarkers in Luminal A Breast Cancer: A Comparative Pilot Study.Biomedicines · 2025Article
- N1 and N2 neutrophil subtypes in breast cancer: functional implications and clinical perspectives: a narrative review.Annals of medicine and surgery (2012) · 2025Review
- Comprehensive analysis of the systemic immune landscape across breast cancer subtypes and disease stages.Immuno-oncology technology · 2025Article
- Understanding and reversing mammary tumor-driven reprogramming of myelopoiesis to reduce metastatic spread.Cancer cell · 2025Article
- Distinct proteomic profiles of plasma-derived extracellular vesicles in healthy, benign, and triple-negative breast cancer: candidate biomarkers for liquid biopsy.Scientific reports · 2025Article
- Leveraging Immunological Properties of Nucleic Acid Nanoparticles to Improve Cancer Therapy.RNA nanomed · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Cancer disrupts intratumoral innate-adaptive immune crosstalk, but how the systemic immune landscape evolves during breast cancer progression remains unclear. We profiled circulating immune cells in stage I-III and stage IV triple-negative breast cancer (TNBC) patients and healthy donors (HDs). Metastatic TNBC (mTNBC) patients had reduced T cells, dendritic cells, and differentiated B cells compared to non-metastatic TNBC patients and HDs, partly linked to prior chemotherapy. Vδ1 γδ T cells from mTNBC patients produced more IL17 than those from HDs. Chemotherapy-naïve mTNBC patients showed increased classical monocytes and neutrophils. Transcriptional, proteomic, and functional analyses revealed that neutrophils in mTNBC exhibited enhanced migratory capacity, elevated granule proteins, and higher ROS production. Some immune changes, such as reduced non-switched B cells and heightened neutrophil migration, were evident in earlier TNBC stages. This study comprehensively maps systemic immunity in TNBC, guiding future research on patient stratification and immunomodulation strategies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.